Copyright ©The Author(s) 2023.
World J Gastrointest Oncol. Oct 15, 2023; 15(10): 1691-1705
Published online Oct 15, 2023. doi: 10.4251/wjgo.v15.i10.1691
Figure 1
Figure 1 The location of a tumor within the pancreas affects a patient's presentation.
Figure 2
Figure 2 Targeted therapies used in systemic treatment of advanced pancreatic cancers. AKT: Protein kinase B; VEGFR: Vascular epidermal growth factor receptor; ERK: Extracellular signal-related kinase; FGFR: Fibroblast growth factor receptor; GTP: Guanosine triphosphate; MEK: Mitogen-activated protein kinase; mTOR: Mammalian target of rapamycin; NTRK: Neurotrophic tyrosine receptor kinase; PI3K: Phosphoinositide-3-kinase; PKD1: Polycystic kidney disease 1; RAF: Raf proto-oncogene; RAS: RAS proto-oncogene.
Figure 3
Figure 3 Treatment with immune check point inhibitors for advanced pancreatic cancer. CTLA4: Cytotoxic T-lymphocyte-associated protein 4; MHC: Major histocompatibility complex; PD-1: Programmed cell death protein 1; PD-L1: Programmed death-ligand 1; TCR: T cell receptor.